The emerging treatment landscape of targeted therapy in non-small-cell lung cancer

[1]  P. Jänne,et al.  Safety and preliminary antitumor activity of U3-1402: A HER3-targeted antibody drug conjugate in EGFR TKI-resistant, EGFRm NSCLC. , 2019, Journal of Clinical Oncology.

[2]  Sung Sook Lee,et al.  Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M–Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[3]  Charu Aggarwal,et al.  Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study. , 2019, The Lancet. Respiratory medicine.

[4]  C. Blakely,et al.  Emerging Targeted Therapies for the Treatment of Non-small Cell Lung Cancer , 2019, Current Oncology Reports.

[5]  S. Lippman,et al.  Novel Third-Generation EGFR Tyrosine Kinase Inhibitors and Strategies to Overcome Therapeutic Resistance in Lung Cancer. , 2019, Cancer research.

[6]  F. Barlesi,et al.  Alectinib in the treatment of ALK-positive metastatic non-small cell lung cancer: clinical trial evidence and experience with a focus on brain metastases , 2019, Therapeutic advances in respiratory disease.

[7]  Yan Zhang,et al.  miRNA-223 is an anticancer gene in human non-small cell lung cancer through the PI3K/AKT pathway by targeting EGFR , 2019, Oncology reports.

[8]  R. Kratzke,et al.  JAK/STAT inhibition with ruxolitinib enhances oncolytic virotherapy in non-small cell lung cancer models , 2019, Cancer Gene Therapy.

[9]  A. Tafreshi,et al.  Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Liang Ma,et al.  microRNA‐148a‐3p inhibited the proliferation and epithelial–mesenchymal transition progression of non‐small‐cell lung cancer via modulating Ras/MAPK/Erk signaling , 2018, Journal of cellular physiology.

[11]  Wei Sun,et al.  miR-202 Enhances the Anti-Tumor Effect of Cisplatin on Non-Small Cell Lung Cancer by Targeting the Ras/MAPK Pathway , 2018, Cellular Physiology and Biochemistry.

[12]  K. Nishio,et al.  An HER3-targeting antibody–drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC , 2018, Oncogene.

[13]  L. Paz-Ares,et al.  KRAS-Mutant non-small cell lung cancer: From biology to therapy. , 2018, Lung cancer.

[14]  A. Tafreshi,et al.  Pembrolizumab plus Chemotherapy for Squamous Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[15]  Chunmei Wang,et al.  miRNA‑328 overexpression confers cisplatin resistance in non‑small cell lung cancer via targeting of PTEN. , 2018, Molecular medicine reports.

[16]  S. Gettinger,et al.  Nivolumab Plus Erlotinib in Patients With EGFR‐Mutant Advanced NSCLC , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[17]  Tingting Zhang,et al.  Downregulation of MicroRNA-135 Promotes Sensitivity of Non-Small Cell Lung Cancer to Gefitinib by Targeting TRIM16. , 2018, Oncology research.

[18]  Joe Y. Chang,et al.  NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018. , 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

[19]  D. Raben,et al.  The Integration of Radiotherapy with Immunotherapy for the Treatment of Non–Small Cell Lung Cancer , 2018, Clinical Cancer Research.

[20]  M. Hasmann,et al.  Clinical development of HER3-targeting monoclonal antibodies: Perils and progress. , 2018, Cancer treatment reviews.

[21]  A. Gemma,et al.  Phase III study comparing bevacizumab plus erlotinib to erlotinib in patients with untreated NSCLC harboring activating EGFR mutations: NEJ026. , 2018 .

[22]  Stephen Broderick,et al.  Neoadjuvant PD‐1 Blockade in Resectable Lung Cancer , 2018, The New England journal of medicine.

[23]  J. Mazières,et al.  136PD_PR 3-year survival and duration of response in randomized phase II study of atezolizumab (atezo) vs docetaxel (doc) in 2L+ NSCLC (POPLAR) , 2018 .

[24]  David C. Smith,et al.  Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  S. Gettinger,et al.  Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  P. Forde,et al.  Neoadjuvant and consolidation immuno-oncology therapy in stage III non-small cell lung cancer. , 2018, Journal of thoracic disease.

[27]  Roy S. Herbst,et al.  The biology and management of non-small cell lung cancer , 2018, Nature.

[28]  Ying Cheng,et al.  Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[29]  P. Jänne,et al.  CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  Hongwei Liang,et al.  MiR-193a-3p is an Important Tumour Suppressor in Lung Cancer and Directly Targets KRAS , 2017, Cellular Physiology and Biochemistry.

[31]  Xiaoping Zhou,et al.  Inhibition of miR-23a increases the sensitivity of lung cancer stem cells to erlotinib through PTEN/PI3K/Akt pathway. , 2017, Oncology reports.

[32]  F. Peng,et al.  Acquired resistance to crizotinib in advanced lung adenocarcinoma with MET exon 14 skipping. , 2017, Lung cancer.

[33]  Mahaveer Singh,et al.  Targeting non-small cell lung cancer with small-molecule EGFR tyrosine kinase inhibitors. , 2017, Drug discovery today.

[34]  P. Hammond,et al.  A Combination RNAi-Chemotherapy Layer-by-Layer Nanoparticle for Systemic Targeting of KRAS/P53 with Cisplatin to Treat Non–Small Cell Lung Cancer , 2017, Clinical Cancer Research.

[35]  J. Baselga,et al.  A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer , 2017, BMC Cancer.

[36]  Tarek Mekhail,et al.  Durvalumab after Chemoradiotherapy in Stage III Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.

[37]  S. Sleijfer,et al.  Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity , 2017, Clinical Cancer Research.

[38]  K. Kelnar,et al.  Synergy between next generation EGFR tyrosine kinase inhibitors and miR-34a in the inhibition of non-small cell lung cancer. , 2017, Lung cancer.

[39]  U. Dafni,et al.  Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. , 2017, The Lancet. Respiratory medicine.

[40]  W. Curran,et al.  Treatment Design and Rationale for a Randomized Trial of Cisplatin and Etoposide Plus Thoracic Radiotherapy Followed by Nivolumab or Placebo for Locally Advanced Non-Small-Cell Lung Cancer (RTOG 3505). , 2017, Clinical lung cancer.

[41]  Q. Mei,et al.  ING5 knockdown enhances migration and invasion of lung cancer cells by inducing EMT via EGFR/PI3K/Akt and IL-6/STAT3 signaling pathways , 2017, Oncotarget.

[42]  J. Ahn,et al.  EGFR TKI combination with immunotherapy in non-small cell lung cancer , 2017, Expert opinion on drug safety.

[43]  Chunmei Li,et al.  MiR-93 Promotes Tumorigenesis and Metastasis of Non-Small Cell Lung Cancer Cells by Activating the PI3K/Akt Pathway via Inhibition of LKB1/PTEN/CDKN1A , 2017, Journal of Cancer.

[44]  A. Wu,et al.  Alectinib for the management of ALK-positive non-small cell lung cancer brain metastases. , 2017, Journal of thoracic disease.

[45]  Chia-Chi Lin,et al.  Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  M. Ahn,et al.  Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer , 2017, The New England journal of medicine.

[47]  Toshio Shimizu,et al.  Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancer , 2017, Cancer Chemotherapy and Pharmacology.

[48]  Carlos Barrios,et al.  Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial , 2017, The Lancet.

[49]  G. Shapiro,et al.  Phase Ib Study of Safety and Pharmacokinetics of the PI3K Inhibitor SAR245408 with the HER3-Neutralizing Human Antibody SAR256212 in Patients with Solid Tumors , 2016, Clinical Cancer Research.

[50]  Yi-long Wu,et al.  Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following platinum-based chemotherapy (IUNO study). , 2016, Lung cancer.

[51]  T. Mitsudomi,et al.  Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. , 2016, The Lancet. Oncology.

[52]  L. Sequist,et al.  Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. , 2016, The Lancet. Oncology.

[53]  Li Shen,et al.  The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  Y. Shentu,et al.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.

[55]  Fredrik Y Frejd,et al.  Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds , 2016, mAbs.

[56]  Yiping Zhang,et al.  Mutation and prognostic analyses of PIK3CA in patients with completely resected lung adenocarcinoma , 2016, Cancer medicine.

[57]  Jeffrey W. Clark,et al.  Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[58]  K. Yonesaka,et al.  HER3 and its Ligand, Heregulin, as Targets for Cancer Therapy. , 2016, Recent patents on anti-cancer drug discovery.

[59]  D. Jäger,et al.  Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. , 2016, The Lancet. Oncology.

[60]  Tianhong Li,et al.  Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy , 2016, Journal of Hematology & Oncology.

[61]  F. Ciardiello,et al.  Mechanisms of resistance to EGFR-targeted drugs: lung cancer , 2016, ESMO Open.

[62]  Kenneth E. Rosenzweig,et al.  Scientific Advances in Lung Cancer 2015 , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[63]  Keunchil Park,et al.  Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial , 2016, The Lancet.

[64]  Y. Shentu,et al.  Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial , 2016, The Lancet.

[65]  Jae Cheol Lee,et al.  Activation of the IGF1R pathway potentially mediates acquired resistance to mutant-selective 3rd-generation EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer , 2016, Oncotarget.

[66]  K. Kerr,et al.  Non-Small Cell Lung Cancer, PD-L1, and the Pathologist. , 2016, Archives of pathology & laboratory medicine.

[67]  P. Jänne,et al.  Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib , 2016, Oncogene.

[68]  Yuan Hu,et al.  Enhanced Antitumor Activity of Cetuximab in Combination with the Jak Inhibitor CYT387 against Non-Small-Cell Lung Cancer with Various Genotypes. , 2016, Molecular pharmaceutics.

[69]  L. Crinò,et al.  Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications , 2016, Expert review of respiratory medicine.

[70]  P. Jänne,et al.  ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non–Small Cell Lung Cancer , 2015, Clinical Cancer Research.

[71]  M. Cañadas-Garre,et al.  PTEN and PI3K/AKT in non-small-cell lung cancer. , 2015, Pharmacogenomics.

[72]  S. Sleijfer,et al.  First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors , 2015, Clinical Cancer Research.

[73]  N. Altorki,et al.  Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  K. Syrigos,et al.  Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. , 2015, The Lancet. Oncology.

[75]  L. Crinò,et al.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[76]  M. Nishio,et al.  Phase I study of the HER3-targeted antibody patritumab (U3-1287) combined with erlotinib in Japanese patients with non-small cell lung cancer. , 2015, Lung cancer.

[77]  N. Altorki,et al.  Common and rare EGFR mutations (EGFRm) in the RADIANT trial: Final follow-up with 5 year data. , 2015 .

[78]  J. Lunceford,et al.  Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.

[79]  R. Herbst,et al.  Lung Cancer in the Era of Precision Medicine , 2015, Clinical Cancer Research.

[80]  D. Planchard,et al.  A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[81]  Ying Cheng,et al.  Final Overall Survival Results from a Phase III, Randomized, Placebo-Controlled, Parallel-Group Study of Gefitinib Versus Placebo as Maintenance Therapy in Patients with Locally Advanced or Metastatic Non–Small-Cell Lung Cancer (INFORM; C-TONG 0804) , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[82]  M. Kris,et al.  Adjuvant chemotherapy for resected early-stage non-small cell lung cancer. , 2015, The Cochrane database of systematic reviews.

[83]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[84]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[85]  I. Oh,et al.  Histological transformation from non-small cell to small cell lung carcinoma after treatment with epidermal growth factor receptor-tyrosine kinase inhibitor , 2014, Thoracic cancer.

[86]  Koichi Goto,et al.  Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. , 2014, The Lancet. Oncology.

[87]  Yibang Chen,et al.  Inhibition of the JAK/STAT pathway with ruxolitinib overcomes cisplatin resistance in non-small-cell lung cancer NSCLC , 2014, Apoptosis.

[88]  Xing Chen,et al.  MicroRNA-34a overcomes HGF-mediated gefitinib resistance in EGFR mutant lung cancer cells partly by targeting MET. , 2014, Cancer letters.

[89]  Ruey-min Lee,et al.  Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. , 2014, The Lancet. Oncology.

[90]  P. Petronini,et al.  Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer. , 2014, Biochemical pharmacology.

[91]  B. Jiang,et al.  Alteration in Mir-21/PTEN Expression Modulates Gefitinib Resistance in Non-Small Cell Lung Cancer , 2014, PloS one.

[92]  William Pao,et al.  AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. , 2014, Cancer discovery.

[93]  M. Kris,et al.  SELECT: A multicenter phase II trial of adjuvant erlotinib in resected early-stage EGFR mutation-positive NSCLC. , 2014 .

[94]  A. Delmonte,et al.  Targeting ALK in patients with advanced non small cell lung cancer: biology, diagnostic and therapeutic options. , 2014, Critical reviews in oncology/hematology.

[95]  G. Giaccone,et al.  A phase 2 trial of dacomitinib (PF‐00299804), an oral, irreversible pan‐HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non–small cell lung cancer after failure of prior chemotherapy and erlotinib , 2014, Cancer.

[96]  S. Thongprasert,et al.  A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER) , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[97]  C. Obasaju,et al.  PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[98]  M. Rubin,et al.  ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[99]  Michael Peyton,et al.  Comprehensive Biomarker Analysis and Final Efficacy Results of Sorafenib in the BATTLE Trial , 2013, Clinical Cancer Research.

[100]  N. Ishii,et al.  Enhanced antitumor activity of erlotinib in combination with the Hsp90 inhibitor CH5164840 against non‐small‐cell lung cancer , 2013, Cancer science.

[101]  L. Sequist,et al.  Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[102]  H. Groen,et al.  Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[103]  Tae Min Kim,et al.  Heterogeneity of Genetic Changes Associated with Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancer , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[104]  T. Betsuyaku,et al.  Activation of the FGF2-FGFR1 Autocrine Pathway: A Novel Mechanism of Acquired Resistance to Gefitinib in NSCLC , 2013, Molecular Cancer Research.

[105]  Tianhong Li,et al.  Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[106]  William Pao,et al.  Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers , 2013, Clinical Cancer Research.

[107]  P. Harari,et al.  Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation. , 2013, Cancer research.

[108]  Levi A Garraway,et al.  Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. , 2012, Cancer discovery.

[109]  M. Ladanyi,et al.  HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. , 2012, Cancer discovery.

[110]  Yan Sun,et al.  Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. , 2012, The Lancet. Oncology.

[111]  Hyae-Young Kim,et al.  First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[112]  E. Felip,et al.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. , 2012, The Lancet. Oncology.

[113]  J. Sun,et al.  EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers , 2011, Nature Medicine.

[114]  C. Croce,et al.  EGFR and MET receptor tyrosine kinase–altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers , 2011, Nature Medicine.

[115]  Jun Ma,et al.  Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. , 2011, The Lancet. Oncology.

[116]  R. Eisenberg,et al.  Protein inhibitor of activated STAT3 expression in lung cancer , 2011, Molecular oncology.

[117]  M. Ladanyi,et al.  Impact on Disease-Free Survival of Adjuvant Erlotinib or Gefitinib in Patients with Resected Lung Adenocarcinomas that Harbor EGFR Mutations , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[118]  Dhara N. Amin,et al.  The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics. , 2010, Seminars in cell & developmental biology.

[119]  Jeffrey W. Clark,et al.  Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. , 2010, The New England journal of medicine.

[120]  P. Jänne,et al.  The biology and treatment of EML4-ALK non-small cell lung cancer. , 2010, European journal of cancer.

[121]  A. Gemma,et al.  F1000 highlights , 2010 .

[122]  S. Lai,et al.  Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches. , 2010, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[123]  G. Giaccone,et al.  Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. , 2010, The Lancet. Oncology.

[124]  M. Zhong,et al.  MicroRNAs reduce tumor growth and contribute to enhance cytotoxicity induced by gefitinib in non-small cell lung cancer. , 2010, Chemico-biological interactions.

[125]  R. Radhakrishnan,et al.  ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation , 2010, Proceedings of the National Academy of Sciences.

[126]  Y. Yatabe,et al.  Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer , 2010, The FEBS journal.

[127]  T. Mok,et al.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.

[128]  S. Digumarthy,et al.  Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[129]  Richard J Stephens,et al.  Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[130]  Joon-Oh Park,et al.  MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2007, Science.

[131]  Roy S Herbst,et al.  KRAS Mutation Is an Important Predictor of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer , 2007, Clinical Cancer Research.

[132]  K. Shokat,et al.  Escape from HER family tyrosine kinase inhibitor therapy by the kinase inactive HER3 , 2007, Nature.

[133]  Robert Gray,et al.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.

[134]  H. Sasaki,et al.  PIK3CA mutation status in Japanese lung cancer patients. , 2006, Lung cancer.

[135]  M. Nishimura,et al.  A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations , 2006, British Journal of Cancer.

[136]  J. Buckner,et al.  A Phase I and Pharmacokinetic Study of Temsirolimus (CCI-779) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients with Advanced Cancer , 2006, Clinical Cancer Research.

[137]  G. Barton,et al.  Emerging roles of pseudokinases. , 2006, Trends in cell biology.

[138]  Shile Huang,et al.  Curcumin inhibits the mammalian target of rapamycin‐mediated signaling pathways in cancer cells , 2006, International journal of cancer.

[139]  J. Minna,et al.  Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. , 2006, Journal of the National Cancer Institute.

[140]  Yih-Leong Chang,et al.  Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer , 2006, International journal of cancer.

[141]  C. Mermel,et al.  ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[142]  D. Auclair,et al.  BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.

[143]  R. Wilson,et al.  EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[144]  N. Sonenberg,et al.  Upstream and downstream of mTOR. , 2004, Genes & development.

[145]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[146]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[147]  Enrique Casado,et al.  PI3K/Akt signalling pathway and cancer. , 2004, Cancer treatment reviews.

[148]  M. Sliwkowski,et al.  An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. , 2003, Molecular cell.

[149]  M. Perry,et al.  Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[150]  Hyun-soo Cho,et al.  EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. , 2003, Molecular cell.

[151]  Jae-Hoon Kim,et al.  Crystal Structure of the Complex of Human Epidermal Growth Factor and Receptor Extracellular Domains , 2002, Cell.

[152]  P. Dennis,et al.  Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. , 2001, Cancer research.

[153]  J. Darnell,et al.  The role of STATs in transcriptional control and their impact on cellular function , 2000, Oncogene.

[154]  O. Brodin,et al.  Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials , 1995 .

[155]  Sitanshu S. Singh,et al.  Genotype Driven Therapy for Non-Small Cell Lung Cancer: Resistance, Pan Inhibitors and Immunotherapy. , 2019, Current medicinal chemistry.

[156]  Ying Cheng,et al.  Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. , 2018, The Lancet. Oncology.

[157]  S. Gettinger,et al.  Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. , 2017, The Lancet. Oncology.

[158]  A. Jemal,et al.  Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.

[159]  K. O'Byrne,et al.  Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[160]  J. Engelman,et al.  Acquired resistance to crizotinib from a mutation in CD74-ROS1. , 2013, The New England journal of medicine.

[161]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[162]  Jianxing He,et al.  Role of pemetrexed and platinums combination in patients with non-small cell lung cancer. , 2010, Current drug targets.

[163]  J. Downward.  Targeting RAS signalling pathways in cancer therapy , 2003, Nature Reviews Cancer.

[164]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[165]  Alfred A. Bartolucci,et al.  Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials , 1996 .

[166]  Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. , 1995, BMJ.